Gracell Biotechnologies Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gracell Biotechnologies Co. Ltd.
As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.
One week into 2024 and there have already been multiple deals between Chinese innovative drug developers and multinational partners, along with the significant acquisition of GracellBio by AstraZeneca. In this Chinese-language podcast, Brian Yang and Dexter Yan invite a guest speaker to discuss the reasons behind the particularly active China biotech deal-making scene.
Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.
The UK drug maker’s latest deal marks the largest China biotech M&A deal to date, amid the lingering doom and gloom surrounding the fast emerging but cash-constrained sector.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.